Axsome Therapeutics Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $49.1M | $15.6M | $86.5M |
| FY2022 | $94.3M | $109.6M | $200.8M |
| FY2023 | $178.1M | $191.0M | $386.2M |
| FY2024 | $180.7M | $57.0M | $315.4M |
| FY2025 | $117.7M | $88.3M | $322.9M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $49.1M | $15.6M | $86.5M |
| FY2022 | $94.3M | $109.6M | $200.8M |
| FY2023 | $178.1M | $191.0M | $386.2M |
| FY2024 | $180.7M | $57.0M | $315.4M |
| FY2025 | $117.7M | $88.3M | $322.9M |